UBS Group’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.1M Buy
2,888,418
+447,835
+18% +$1.7M ﹤0.01% 3346
2025
Q4
$8.47M Buy
2,440,583
+2,135,810
+701% +$9.5M ﹤0.01% 3466
2025
Q3
$1.69M Buy
304,773
+109,446
+56% +$445K ﹤0.01% 5121
2025
Q2
$482K Buy
195,327
+77,647
+66% +$120K ﹤0.01% 6036
2025
Q1
$234K Sell
117,680
-100,506
-46% -$256K ﹤0.01% 6435
2024
Q4
$637K Buy
218,186
+183,165
+523% +$643K ﹤0.01% 5670
2024
Q3
$136K Buy
35,021
+12,482
+55% +$57.8K ﹤0.01% 6144
2024
Q2
$116K Sell
22,539
-19,984
-47% -$121K ﹤0.01% 6078
2024
Q1
$298K Buy
42,523
+11,111
+35% +$84.3K ﹤0.01% 5577
2023
Q4
$278K Sell
31,412
-12,360
-28% -$95.2K ﹤0.01% 5552
2023
Q3
$418K Sell
43,772
-55,267
-56% -$718K ﹤0.01% 4797
2023
Q2
$1.45M Buy
99,039
+94,104
+1,907% +$1.31M ﹤0.01% 3859
2023
Q1
$60.7K Buy
4,935
+3,726
+308% +$60.7K ﹤0.01% 6301
2022
Q4
$22.5K Buy
+1,209
New +$21.8K ﹤0.01% 7537

Other funds holding PRME